1. Scrip
  2. >>R&D
  3. >>Clinical Trials

Sage’s Biogen-Partnered Essential Tremor Drug Fails In Phase II

Companies Discontinue Development In ET

 
• By Mandy Jackson

For Sage, the mid-stage failure of SAGE-324 in essential tremor is its second setback in a year full of clinical trial readouts. For Biogen, it highlights a lack of later-stage pipeline prospects.

Uncontrollable hand or another parts of body. Slowness of movement or stiffness of the limbs and trunk.
The companies are evaluating indications beyond essential tremor • Source: Shutterstock

Sage Therapeutics, Inc. and partner Biogen, Inc. revealed on 24 July that SAGE-324, a positive allosteric modulator (PAM) of the GABA-A receptor, did not meet the primary endpoint in a Phase II dose-ranging study in essential tremor (ET). The clinical trial failure is Sage’s second mid-stage upset this year and the setback eliminates a needed later-stage program from Biogen’s pipeline.

Key Takeaways

  • Sage and Biogen will discontinue development of SAGE-324 in essential tremor after all doses of the drug failed on the primary endpoint in the Phase II...

The companies said they will end development of SAGE-324 in ET while evaluating next steps in other potential indications. Analysts said in same-day notes that they viewed the Phase II...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

Kymera STAT6 Data Set The Bar For ‘Dupixent-In-A-Pill’ Race

 
• By Jessica Merrill

Kymera will move KT-621 into Phase II trials later this year based on compelling data in healthy volunteers, validating the company’s protein-degradation platform.

ASCO: Zepzelca Tecentriq Combo A Lung Cancer Success For Jazz and Roche

 
• By Andrew McConaghie

Small-cell lung cancer treatment is rapidly evolving, but Jazz and Roche are set to create a new maintenance therapy setting with their Zepzelca plus Tecentriq combination.

Atai/Beckley Merger Comes At A Transformative Time For Psychedelics

 
• By Kevin Grogan

All eyes are on the upcoming readout of BPL-003 for treatment-resistant depression.

Stock Watch: How GSK’s Nucala Info Drip Helped Share Price

 
• By Andy Smith

The information flow in the months before the approval of GSK’s Nucala in COPD provides an interesting case study, and brings to mind the cautionary tale of Alnylam’s Onpattro.

More from R&D

Stock Watch: How GSK’s Nucala Info Drip Helped Share Price

 
• By Andy Smith

The information flow in the months before the approval of GSK’s Nucala in COPD provides an interesting case study, and brings to mind the cautionary tale of Alnylam’s Onpattro.

ASCO: J&J Banks On T-Cell Engager’s Safety In Prostate Cancer

 
• By Andrew McConaghie

The company highlighted the KLK2-targeting agent’s safety at ASCO but it may have to rely on combinations to make pasritamig competitive.

ASCO: Regeneron Looks To Become Bigger Immuno-Oncology Player

 
• By Alaric DeArment

The drugmaker presented oral abstracts at the meeting for Libtayo in adjuvant cutaneous squamous-cell carcinoma and linvoseltamab in multiple myeloma.